{
    "nctId": "NCT00816582",
    "briefTitle": "PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer",
    "officialTitle": "A Phase II Clinical Trial to Evaluate 18F-Fluoroestradiol Positron Emission Tomography / Computerized Tomography (PET/CT) Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 17,
    "primaryOutcomeMeasure": "Clinical Benefit Rate (CBR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* post-menopausal (\u2265 60 years old, or age \u2265 45 years with amenorrhea for \\> 12 months or follicle stimulating hormone and estrogen levels within post-menopausal range, or prior bilateral oophorectomy)\n* hormone receptor positive (ER and/or PgR) disease as determined locally\n* WHO performance status 0-2\n* life expectancy of \u2265 3 months\n* the presence of at least one measurable or evaluable (non-measurable) lesion\n* informed consent prior to any study procedures\n\nExclusion Criteria:\n\n* life threatening metastatic visceral disease\n* brain or leptomeningeal metastases\n* prior exposure to fulvestrant\n* history of bleeding diathesis or need for long term anti-coagulation",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}